Retrospective Case Study Examining the Utility of In Vitro Bioactivity as a Conservative Point of Departure

Overall goal/objectives:

To elucidate whether a “region of safety” (ROS), i.e. a threshold below which no bioactivity or toxicity would be anticipated, can be identified using NAMs for a list of chemicals with existing human health evaluations.

Case Study Leader:

US EPA (Katie Paul Friedman), ECHA (Tomasz Sobanski)

Collaborators:

US EPA (ORD), ECHA, EFSA, A*STAR

Status: Completed

Presentations or publications that have been publicly released:

  • Paul Friedman K, Gagne M, Loo LH, Karamertzanis P, Netzeva T, Sobanski T, Franzosa JA, Richard AM, Lougee RR, Gissi A, Lee JJ, Angrish M, Dorne JL, Foster S, Raffaele K, Bahadori T, Gwinn MR, Lambert J, Whelan M, Rasenberg M, Barton-Maclaren T, Thomas RS. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. Toxicol Sci. 2020 Jan 1;173(1):202-225. doi: 10.1093/toxsci/kfz201. PMID: 31532525; PMCID: PMC7720780. https://pubmed.ncbi.nlm.nih.gov/31532525/
Search Here